EYPT - EyePoint Pharmaceuticals GAAP EPS of -$0.49 beats by $0.16 revenue of $10.01M misses by $0.91M
- EyePoint Pharmaceuticals press release ( NASDAQ: EYPT ): Q3 GAAP EPS of -$0.49 beats by $0.16 .
- Revenue of $10.01M (+10.5% Y/Y) misses by $0.91M .
- Cash and investments at September 30, 2022 totaled $157.3 million compared to $171.2 million at June 30, 2022.
- We expect the cash, cash equivalents and investments on hand on September 30, 2022 and expected net cash inflows from our product sales will enable us to fund our current and planned operations into the second half of 2024.
For further details see:
EyePoint Pharmaceuticals GAAP EPS of -$0.49 beats by $0.16, revenue of $10.01M misses by $0.91M